Slow cell growth after bone marrow transplantation may be due to a lower volume of hematopoietic stem cell return and a higher dose of alkylating agent in the pre-transplant pretreatment regimen. It is also possible that the patient himself has a poor bone marrow microenvironment, such as in patients with primary myelofibrosis.
1. The rate of blood cell growth after successful bone marrow transplantation is related to the amount of hematopoietic stem cells infused; the more hematopoietic stem cells infused, the better the patient’s normal hematopoietic function of the bone marrow is restored. On the contrary, when the amount of hematopoietic stem cells is less, the normal hematopoietic ability of the patient’s bone marrow is relatively weak, so the growth of blood cells is slower.
2. Pretreatment is required before bone marrow transplantation in order to minimize the malignant cells within the bone marrow. Alkylating agents, such as Zoerythromycin and hypertriglycerides, are commonly used in the pretreatment regimen. The use of high doses of alkylating agents can lead to severe myelosuppression, which is not fully recovered after transplantation, resulting in slower cell growth.
In addition, if a patient with primary myelofibrosis has a poor bone marrow microenvironment itself, a similar situation can occur after bone marrow transplantation.
It is recommended that the patient go to the hematology department in time, complete the relevant examinations to clarify the cause of the slow growth of blood cells, deal with the cause of the disease, and receive standardized treatment under the guidance of the physician.